Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.

Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.

Detalles Bibliográficos
Main Authors:	Jadersten, M, Pellagatti, A, Forsblom, A, Emanuelsson, E, Merup, M, Samuelsson, J, Wainscoat, J, Boultwood, J, Hellstorm-Lindberg, E
Formato:	Conference item
Publicado:	2005

Títulos similares

Lenalidomide up-regulates SPARC and inhibits in vitro growth of the malignant clone in myelodysplastic syndrome patients with 5q deletion.
por: Pellagatti, A, et al.
Publicado: (2006)

Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
por: Pellagatti, A, et al.
Publicado: (2007)

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
por: Jädersten, M, et al.
Publicado: (2009)

Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment
por: Scharenberg, C, et al.
Publicado: (2011)

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression
por: Martin Jädersten, et al.
Publicado: (2009-12-01)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome.
por: Pellagatti, A, et al.
Publicado: (2011)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome
por: Pellagatti, A, et al.
Publicado: (2011)

Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion
por: Martin Jädersten
Publicado: (2010-03-01)

Gene expression profiling of day 7 erythroblasts from RARS before and after treatment with G-CSF
por: Nikpour, M, et al.
Publicado: (2007)

Gene expression profiling in the myelodysplastic syndromes.
por: Pellagatti, A, et al.
Publicado: (2005)

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
por: Raza Azra, et al.
Publicado: (2012-04-01)

Hematological features of patients with myelodysplastic syndromes associated with a chromosome 5q deletion.
por: Lewis, S, et al.
Publicado: (1995)

Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells
por: Pellagatti, A, et al.
Publicado: (2009)

Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion
por: Maria Ximeri, et al.
Publicado: (2010-03-01)

The impact of spliceosome mutations in MDS
por: Jacqueline Boultwood, et al.
Publicado: (2019-06-01)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
por: Pellagatti, A, et al.
Publicado: (2010)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
por: Pellagatti, A, et al.
Publicado: (2010)

5q- syndrome.
por: Boultwood, J, et al.
Publicado: (2012)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
por: Pellagatti, A, et al.
Publicado: (2010)

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.
por: Pellagatti, A, et al.
Publicado: (2010)

Clonality in the myelodysplastic syndromes.
por: Boultwood, J, et al.
Publicado: (2001)

TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.
por: Caceres, G, et al.
Publicado: (2013)

Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide
por: Gudrun Göhring, et al.
Publicado: (2011-02-01)

The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes.
por: Nilsson, L, et al.
Publicado: (2007)

Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)—Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q)
por: Axel Rüfer, et al.
Publicado: (2022-07-01)

Molecular pathogenesis of the myelodysplastic syndromes
por: Boultwood, J, et al.
Publicado: (1999)

Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide
por: Virginie Eclache, et al.
Publicado: (2008-02-01)

Gene expression profiling in 5q-syndrome and myelodysplastic syndromes.
por: Pellagatti, A, et al.
Publicado: (2003)

Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes.
por: Pellagatti, A, et al.
Publicado: (2009)

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome (MDS)
por: Botezatu, L, et al.
Publicado: (2016)

Durable Hematological and Major Cytogenetic Response in a Patient with Isolated 20q Deletion Myelodysplastic Syndrome Treated with Lenalidomide
por: Bagi Jana, et al.
Publicado: (2014-01-01)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes with and without a del(5q)
por: Pellagatti, A, et al.
Publicado: (2005)

Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome.
por: Boultwood, J, et al.
Publicado: (2012)

Telomere length in myelodysplastic syndromes.
por: Boultwood, J, et al.
Publicado: (1995)

Haploinsufficiency of RPS14 and Deregulation of Ribosomal- and Translation-Related Genes in MDS Patients with Del(5q)
por: Pellagati, A, et al.
Publicado: (2008)

Advances in the 5q- syndrome.
por: Boultwood, J, et al.
Publicado: (2010)

Expression profiling of CD34+cells in patients with myelodysplastic syndromes with and without a del(5q).
por: Pellagatti, A, et al.
Publicado: (2004)

The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells
por: Brigitte Mohr, et al.
Publicado: (2009-03-01)

PB2169: LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE COMBINATION THERAPY IN CONCOMITANT MYELODYSPLASTIC SYNDROME WITH ISOLATED 5Q DELETION AND MULTIPLE MYELOMA
por: Yu Han Koh, et al.
Publicado: (2023-08-01)

PP2A: The Achilles Heal in MDS with 5q Deletion
por: David eSallman, et al.
Publicado: (2014-09-01)